CAICaris Life Sciences, Inc.
What is the market doing?
No clear lean: nothing decisive, though in an uptrend.
In an uptrend, above its rising 50- and 200-day averages. Price is +48% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 22, 2026; selling is often routine (taxes, diversification).
Moderately shorted, settled Sep 30, 2026, a few days of normal trading to cover. Up 4.2% since the previous count, down from 5.0% of shares outstanding three months ago.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How CAI is trading
Caris Life Sciences, Inc. is +0.16% over the past year while the S&P 500 is +16%: 16 points behind the market.
1-year return · S&P 500 +16%
- vs 200-day average
- +48%
vs 200-day average · a clear uptrend
- RSI (14)
- 57
RSI (14) · neutral
- Below its 52-week high
- 1.0%
Below its 52-week high
Details›
- Last close2026-10-23
- $32.00
- 1 monthS&P 500 −0.94%
- −0.84%
- 1 yearS&P 500 +16%
- +0.16%
- vs 50-day average$27.87
- +15%
- 52-week high
- $32.33
- 52-week low
- $14.55
- Annualised volatility
- 65%
- Insider selling, net, 6 monthsForms 3/4/5 to 2026-10-22
- $26M
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Where the price stands
Its trend against the 50-day and 200-day averages, and the levels it keeps coming back to.
What it has returned
With dividends, year by year, month by month, and by calendar month on average.
Biotechnology
The closest names by size in the same industry